- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05334108
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study to Evaluate the Effects of Repeat Titrated Doses of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport in Healthy Subjects
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78209
- ICON Early Phase Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subjects or female subjects of non-childbearing potential
- ≥18 and <55 years of age at the time of consent
- BMI >18.5 and <30 kg/m2 and a weight of ≥50 kg for males or ≥45 kg for females
- Subjects must be healthy, as determined by the Investigator, based on medical history, physical examination, ECG, and standard panel of blood and laboratory tests at Screening.
- Sexually active males must use a double barrier method of contraception during the study and for at least 90 days after the last dose of study drug
- Male subjects must be willing not to donate sperm until 90 days following the last study drug administration
Exclusion Criteria:
- Personal or family History of significant medical illness
- Clinically significant abnormalities on screening tests/exams
- History of or significant risk of committing suicide
- Donation of plasma within 7 days prior to dosing
- Donation or significant loss of blood within 30 days prior to the first dosing
- Major surgery within 3 months or minor surgery within 1 month prior to admission
- Use of prohibited prescription, over-the-counter medications or natural health products
- Alcohol-based products 24 hours prior to admission
- Female subjects who are currently pregnant or lactating
- Positive pregnancy test
- Use of tobacco or nicotine products within 3 months prior to Screening
- Significant alcohol consumption
- History of drug abuse within the previous 2 years, or a positive drug screen
- History of allergy to study medications
- Undergoing abrupt discontinuation of alcohol or sedatives
- Not suitable for study in the opinion of the Principal Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Cohort 1
ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days Cohort 1 Probe Substrate Cocktail given on 2 separate days:
|
ecopipam HCl ~2mg/kg/day
dextromethorphan, caffeine, omeprazole, and midazolam
|
Other: Cohort 2
ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days Cohort 2 Probe Substrate given on 2 separate days: - bupropion: 100mg oral tablet |
ecopipam HCl ~2mg/kg/day
bupropion
|
Other: Cohort 3
ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days Cohort 3 Probe Substrate Cocktail given on 3 separate days:
|
ecopipam HCl ~2mg/kg/day
dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of dabigatran in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of dabigatran in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of rosuvastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of rosuvastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of dabigatran in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of dabigatran in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of rosuvastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of rosuvastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of dabigatran in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of dabigatran in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of rosuvastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of rosuvastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of dabigatran in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of dabigatran in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of rosuvastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of rosuvastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUC0-24 of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of bupropion (and its 4-hydroxybupropion metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax of bupropion (and its 4-hydroxybupropion metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax omeprazole (and its 5'-hydroxy omeprazole metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Cmax omeprazole (and its 5'-hydroxy omeprazole metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of bupropion (and its 4-hydroxybupropion metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of bupropion (and its 4-hydroxybupropion metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of omeprazole (and its 5'-hydroxy omeprazole metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUCinf of omeprazole (and its 5'-hydroxy omeprazole metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of bupropion (and its 4-hydroxybupropion metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of bupropion (and its 4-hydroxybupropion metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of omeprazole (and its 5'-hydroxy omeprazole metabolite) in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
AUClast of omeprazole (and its 5'-hydroxy omeprazole metabolite) in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for dextromethorphan in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for dextromethorphan in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL for IV midazolam in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL for IV midazolam in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for oral midazolam in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for oral midazolam in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for dabigatran in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for dabigatran in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for pitavastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for pitavastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for rosuvastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for rosuvastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for atorvastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for atorvastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for bupropion in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for bupropion in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for caffeine in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for caffeine in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for omeprazole in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
CL/F for omeprazole in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for dextromethorphan in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for dextromethorphan in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V for IV midazolam in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V for IV midazolam in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for oral midazolam in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for oral midazolam in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for dabigatran in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for dabigatran in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for pitavastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for pitavastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for rosuvastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for rosuvastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for bupropion in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for bupropion in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for atorvastatin in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for atorvastatin in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for caffeine in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for caffeine in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for omeprazole in the presence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
V/F for omeprazole in the absence of ecopipam
Time Frame: Up to Day 22
|
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 22
|
Total concentration of bilirubin in the presence of ecopipam
Time Frame: Up to Day 18
|
Bilirubin sampling will occur on Day 1 and Day 18
|
Up to Day 18
|
Total concentration of bilirubin in the absence of ecopipam
Time Frame: Up to Day 18
|
Bilirubin sampling will occur on Day 1 and Day 18
|
Up to Day 18
|
Unconjugated concentration of bilirubin in the presence of ecopipam
Time Frame: Up to Day 18
|
Bilirubin sampling will occur on Day 1 and Day 18
|
Up to Day 18
|
Unconjugated concentration of bilirubin in the absence of ecopipam
Time Frame: Up to Day 18
|
Bilirubin sampling will occur on Day 1 and Day 18
|
Up to Day 18
|
Conjugated concentration of bilirubin in the presence of ecopipam
Time Frame: Up to Day 18
|
Bilirubin sampling will occur on Day 1 and Day 18
|
Up to Day 18
|
Conjugated concentration of bilirubin in the absence of ecopipam
Time Frame: Up to Day 18
|
Bilirubin sampling will occur on Day 1 and Day 18
|
Up to Day 18
|
Average of the 6-hour plasma dextromethorphan: dextrorphan ratio in the presence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 8-hour plasma dextromethorphan: dextrorphan ratio in the presence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 12-hour plasma dextromethorphan: dextrorphan ratio in the presence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 6-hour plasma dextromethorphan: dextrorphan ratio in the absence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 8-hour plasma dextromethorphan: dextrorphan ratio in the absence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 12-hour plasma dextromethorphan: dextrorphan ratio in the absence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 6-hour plasma caffeine: paraxanthine metabolite ratio in the presence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 8-hour plasma caffeine: paraxanthine metabolite ratio in the presence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 12-hour plasma caffeine: paraxanthine metabolite ratio in the presence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 6-hour plasma caffeine: paraxanthine metabolite ratio in the absence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 8-hour plasma caffeine: paraxanthine metabolite ratio in the absence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Average of the 12-hour plasma caffeine: paraxanthine metabolite ratio in the absence of ecopipam
Time Frame: Up to Day 14
|
6 blood samples will be collected at the indicated time points for pharmacokinetic analysis
|
Up to Day 14
|
Safety and tolerability as demonstrated by the Modified Observer's Assessment of Alertness/Sedation (MOAA/S)
Time Frame: Up to Day 63
|
Score from 0-5 where 0 is no response and 5 is responds readily.
MOAA/S measures will be recorded at the indicated timepoints
|
Up to Day 63
|
Safety and tolerability as demonstrated by the Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: Up to Day 63
|
Safety and tolerability measures will be recorded at the indicated timepoints
|
Up to Day 63
|
Number of participants requiring concomitant medications
Time Frame: Up to Day 63
|
Participants will be continuously monitored for the use of concomitant medications
|
Up to Day 63
|
AEs with relatedness associated with dextromethorphan
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with IV midazolam
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with oral midazolam
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with dabigatran
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with pitavastatin
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with rosuvastatin
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with atorvastatin
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with bupropion
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with caffeine
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with omeprazole
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
AEs with relatedness associated with ecopipam
Time Frame: Up to Day 63
|
Subjects will be continually monitored for adverse events
|
Up to Day 63
|
Absolute values of white blood cell (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelets (1000/mm3)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Absolute values of hematocrit (percent)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Absolute values of hemoglobin (g/dL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Absolute values of Red blood cell (RBC) count (M/mm3)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Absolute values of sodium, potassium, chloride (mmol/L)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of clinical chemistry parameters
|
Up to Day 26
|
Absolute values of magnesium, urea, phosphorus, calcium, glucose, and total, conjugated and unconjugated bilirubin (mg/dL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of clinical chemistry parameters
|
Up to Day 26
|
Absolute values of albumin and total protein (g/dL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of clinical chemistry parameters
|
Up to Day 26
|
Absolute values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), creatinine phosphokinase (CPK), and creatinine (U/L)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of clinical chemistry parameters
|
Up to Day 26
|
Absolute values of urine specific gravity
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of urine pH
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of urine glucose
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of urine protein
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of urine blood
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of urine ketones
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of urine bilirubin and nitrite
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of urobilinogen (Eu/dL)
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of urine leukocytes by dipstick
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge white blood cell (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelets (1000/mm3)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in hematocrit (percent)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in hemoglobin (g/dL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in Red blood cell (RBC) count (M/mm3)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in sodium, potassium, chloride (mmol/L)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of clinical chemistry parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in magnesium, urea, phosphorus, calcium, glucose, and total, conjugated and unconjugated bilirubin (mg/dL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of clinical chemistry parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in albumin and total protein (g/dL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of clinical chemistry parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and creatinine phosphokinase (CPK), and creatinine (U/L)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of clinical chemistry parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urine specific gravity
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urine pH
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urine glucose
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urine protein
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urine blood
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urine ketones
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urine bilirubin and nitrite
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urobilinogen (Eu/dL)
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Change from Day -1 to Day of Discharge in urine leukocytes by dipstick
Time Frame: Up to Day 26
|
Urine samples will be collected for the assessment of urine parameters
|
Up to Day 26
|
Absolute values of electrocardiogram (ECG) parameters: PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) (Milliseconds)
Time Frame: Up to Day 26
|
Twelve-lead ECGs will be obtained with the participant in a supine position after a rest of at least 5 minutes using an automated ECG machine.
PR, QRS, QT, and QTcF intervals will be measured
|
Up to Day 26
|
Change from pre-dose for the respective day in ECG parameters: PR, QRS, QT, and QTcF (Milliseconds)
Time Frame: Up to Day 26
|
Twelve-lead ECGs will be obtained with the participant in a supine position after a rest of at least 5 minutes using an automated ECG machine.
PR, QRS, QT, and QTcF intervals will be measured
|
Up to Day 26
|
Absolute values of oral temperature (degrees Celsius)
Time Frame: Up to Day 26
|
Temperature will be assessed as part of vital signs
|
Up to Day 26
|
Change from pre-dose for the respective day in oral temperature (degrees Celsius)
Time Frame: Up to Day 26
|
Temperature will be assessed as part of vital signs
|
Up to Day 26
|
Absolute values of heart rate (beats/minute)
Time Frame: Up to Day 26
|
Heart rate will be assessed as part of vital signs
|
Up to Day 26
|
Change from pre-dose for the respective day in heart rate (beats/minute)
Time Frame: Up to Day 26
|
Heart rate will be assessed as part of vital signs
|
Up to Day 26
|
Absolute values of respiratory rate (breaths/minute)
Time Frame: Up to Day 26
|
Respiratory rate will be assessed as part of vital signs
|
Up to Day 26
|
Absolute values of systolic blood pressure (SBP) and diastolic blood pressure (DBP) (mmHG)
Time Frame: Up to Day 26
|
Blood pressure will be assessed as part of vital signs
|
Up to Day 26
|
Change from pre-dose for the respective day in SBP and DBP (mmHG)
Time Frame: Up to Day 26
|
Blood pressure will be assessed as part of vital signs
|
Up to Day 26
|
Absolute values of mean corpuscular hemoglobin (MCH) (pg)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Change from Day 1 to Day of Discharge of mean corpuscular hemoglobin (MCH) (pg)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Absolute values of mean corpuscular volume (MCV) (fL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Change from Day 1 to Day of Discharge of mean corpuscular volume (MCV) (fL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Absolute values of mean corpuscular hemoglobin concentration (MCHC) (g/dL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Change from Day 1 to Day of Discharge of mean corpuscular hemoglobin concentration (MCHC) (g/dL)
Time Frame: Up to Day 26
|
Blood samples will be collected for the assessment of hematology parameters
|
Up to Day 26
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EBS-101-HV-104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Interaction
-
Hutchison Medipharma LimitedCompletedFood-drug Interaction | Drug InteractionUnited States
-
University of Southern CaliforniaRecruitingDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingDrug Drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.Enrolling by invitationDrug-drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug Drug InteractionKorea, Republic of
-
ItalfarmacoCompletedDrug-Drug InteractionPortugal
-
Aurinia Pharmaceuticals Inc.CompletedDrug-drug InteractionUnited States
-
Blade TherapeuticsCompletedDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug-drug InteractionAustralia
-
Nanjing Yoko Biomedical Co., Ltd.CompletedDrug-drug InteractionChina
Clinical Trials on Ecopipam
-
Gerald Maguire, MDUniversity of California Riverisde School of MedicineUnknownLanguage Disorders | Speech Disorders | Communication Disorder | Stuttering, Adult | Childhood-onset Fluency DisorderUnited States
-
Emalex Biosciences Inc.RecruitingTourette SyndromeUnited States, Canada
-
Emalex Biosciences Inc.RecruitingTourette DisorderUnited States, Canada, Spain, Poland, Italy, Bulgaria, Denmark, France, Germany, Hungary, Serbia, Romania
-
Emalex Biosciences Inc.CovanceCompletedHealthy VolunteerUnited Kingdom
-
Emalex Biosciences Inc.Psyadon PharmaCompleted
-
Emalex Biosciences Inc.PPD; ClarioCompleted
-
Emalex Biosciences Inc.Syneos Health; NuventraTerminatedDrug-InteractionsUnited States
-
Emalex Biosciences Inc.CompletedTourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States, Poland, France, Canada, Germany
-
Emalex Biosciences Inc.CompletedTourette SyndromeUnited States, Poland, France, Canada, Germany
-
Psyadon PharmaCompletedPathological GamblingUnited States